Finance

Lists
RPRX:NASDAQ
Royalty Pharma plc
$67.72
-1.38%
(-0.95) 1D
$68.20
+0.71% (+0.48)
After hours
Closed: Nov 19, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RPRX...
Open
$68.42
High
$68.98
Low
$67.57
Mkt. cap
38.84B
Avg. vol.
3.37M
Volume
3.25M
Dividend
1.39%
Quarterly dividend
$0.23
Ex-dividend date
Aug 14, 2026
P/E ratio
44.07
52-wk high
$70.37
52-wk low
$37.31
EPS
$1.54
Beta
0.37
Shares outstanding
445.27M
No. of employees
100
Open
$68.42
High
$68.98
Low
$67.57
Mkt. cap
38.84B
Avg. vol.
3.37M
Volume
3.25M
Dividend
1.39%
Quarterly dividend
$0.23
Ex-dividend date
Aug 14, 2026
P/E ratio
44.07
52-wk high
$70.37
52-wk low
$37.31
EPS
$1.54
Beta
0.37
Shares outstanding
445.27M
No. of employees
100
News stories
From web sources and news partners
About Royalty Pharma plc
CEO-
Employees100
Founded1996
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 6 analysts giving stock ratings to RPRX in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for RPRX in the last 3 months.
Highest
Current $67.72
$80.00 (+18.13%)
Average
$72.67 (+7.31%)
Lowest
$63.00 (-6.97%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Nedelcovych
TD Cowen
Buy
Maintained
$80.00
+18.1%
11/18/2026
Terence Flynn
Morgan Stanley
Buy
Reiterated
$75.00
+10.8%
11/05/2026
Geoff Meacham
Citi
Buy
Maintained
$78.00
+15.2%
11/05/2026
Chris Schott
J.P. Morgan
Buy
Maintained
$74.00
+9.3%
11/04/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
$63.00
-7%
10/09/2026
Ashwani Verma
UBS
Buy
Reiterated
$66.00
-2.5%
09/08/2026
Asad Haider
Goldman Sachs
Buy
Maintained
$66.00
-2.5%
08/06/2026
Umer Raffat
Evercore ISI
Hold
Maintained
-
-
02/12/2026
Last report
Nov 4, 2026
Fiscal period
Q3 2026
$1.21 / $1.18
+2.35%beat
Revenue / Est. (USD)
690.10M / 884.84M
-22.01%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
621.99M
630.58M
674.14M
690.10M
Cost of goods sold
23.10M
-197.48M
268.22M
-88.32M
Cost of revenue
23.10M
-197.48M
268.22M
-88.32M
Research and development expenses
50.50M
39.79M
97.85M
63.16M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
193.87M
159.49M
161.89M
150.10M
Operating expense
240.10M
195.58M
272.81M
217.23M
Total operating expenses
263.21M
-1.90M
541.02M
128.91M
Operating income
358.78M
632.48M
133.12M
561.20M
Other non operating income
-9.17M
-2.20M
-1.50M
-1.88M
EBT including unusual items
355.91M
468.26M
81.49M
266.64M
EBT excluding unusual items
266.52M
564.54M
47.21M
483.39M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
214.20M
294.69M
17.88M
144.68M
Net profit margin
34.44%
46.73%
2.65%
20.96%
Earnings per share
1.47
1.30
1.32
1.21
Interest and investment income
7.07M
6.23M
5.13M
5.34M
Interest expense
-94.17M
-93.72M
-93.62M
-90.49M
Net interest expenses
-87.10M
-87.49M
-88.49M
-85.15M
Depreciation and amortization charges
-
-
-
-
EBITDA
359.98M
633.65M
134.41M
562.42M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps